Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 2/20 | 0.55 |
| ▸ | NMT1 | P30419 | 2/20 | 0.55 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.43 |
| ▸ | NPY1R | P25929 | 3/20 | 0.43 |
| ▸ | NPY4R | P50391 | 3/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23617743 | 0.95 | TLR2 (0.52) | NMT2NMT1TLR2GLP1RNOD1 | |
| SCHEMBL18879495 | 0.95 | TLR2 (0.52) | NMT2NMT1TLR2GLP1RNOD1 | |
| SCHEMBL20016499 | 0.94 | NMT1 (0.50) | NMT2NMT1TLR2GLP1RNPY5R | |
| SCHEMBL18513229 | 0.93 | NMT2 (0.49) | NMT2NMT1TLR2GLP1RNPY5R | |
| SCHEMBL23016452 | 0.93 | NMT2 (0.49) | NMT2NMT1TLR2GLP1RNPY5R | |
| SCHEMBL22023691 | 0.92 | NMT2 (0.48) | NMT2NMT1TLR2GLP1RNOD1 | |
| SCHEMBL18879488 | 0.91 | TLR2 (0.48) | NMT2NMT1TLR2GLP1RNOD1 | |
| SCHEMBL20756558 | 0.90 | NMT1 (0.56) | NMT2NMT1TLR2GLP1RNPY5R | |
| SCHEMBL22227374 | 0.90 | TLR2 (0.48) | NMT2NMT1TLR2GLP1RNOD1 | |
| SCHEMBL19062200 | 0.90 | NMT2 (0.47) | NMT2NMT1TLR2GLP1RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270609-A1 | Single-Stranded RNAI Oligonucleotides Targeting APOC-III | IONIS PHARMACEUTICALS, INC. (US) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270609-A1 | Single-Stranded RNAI Oligonucleotides Targeting APOC-III | APOB, APOL1, RBM3 | NMT2 3275/4885NMT1 3577/4885TLR2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.